Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid t...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 948 4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

NetworkNewsWire Jun. 22 at 3:48 PM

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ONCO.AQL $ONNVF $AZN $APRE $BOLD $FHTX https://ibn.fm/zrVjp

0 · Reply

focafoca99 Jun. 17 at 8:32 PM

$APRE authorized a shareholder‑approved reverse stock split of its common stock.

1 · Reply

VinWeezel Jun. 9 at 12:22 PM

$APRE

0 · Reply

DARKP00L Jun. 1 at 1:58 PM

$APRE 08:08 on Jun. 01 2026 Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors #tradeideas

0 · Reply

Bank_of_Gotham May. 20 at 6:35 PM

$APRE Added here just buyers on low volume these are the stocks I love

0 · Reply

Bulltrader988 May. 19 at 9:24 PM

$APRE 13 G filled on 2026-05-15: Vestal Point Capital, LP 22,654,832 shares 9.9 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1781983/000090266426002544/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply